CHRS - Latest News
Coherus Oncology, Inc. (CHRS), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $165.3M. Beta to the broader market is 0.99.
The article list below shows the most recent CHRS headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent CHRS Headlines
Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026
globenewswire.com - Oct 14, 2026
REDWOOD CITY, Calif. , Oct.
Comparing Coherus Oncology (NASDAQ:CHRS) and Molecular Partners (NASDAQ:MOLN)
defenseworld.net - Oct 5, 2026
Molecular Partners (NASDAQ: MOLN - Get Free Report) and Coherus Oncology (NASDAQ: CHRS - Get Free Report) are both small-cap healthcare companies, but
Contrasting Emergent Biosolutions (NYSE:EBS) and Coherus Oncology (NASDAQ:CHRS)
defenseworld.net - Sep 28, 2026
Coherus Oncology (NASDAQ: CHRS - Get Free Report) and Emergent Biosolutions (NYSE: EBS - Get Free Report) are both small-cap healthcare companies, but
Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets
globenewswire.com - Sep 23, 2026
- Oppenheimer Initiates a Robust Process with Global Reach for the Benefit of Shareholders - - Oppenheimer Initiates a Robust Process with Global Reac
Coherus Oncology, Inc. (CHRS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
seekingalpha.com - Sep 16, 2026
Coherus Oncology, Inc.
How News Affects CHRS Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track CHRS's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked CHRS news questions
- What is the latest CHRS news headline?
- The most recent CHRS headline (Oct 14, 2026) is "Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the CHRS news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What CHRS news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual CHRS options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.